Washington, District of Columbia 20037

  • Aortic Valve Stenosis


The TVT Registry™ is a benchmarking tool developed to track patient safety and real-world outcomes related to the transcatheter aortic valve replacement (TAVR) procedure. Created by The Society of Thoracic Surgeons (STS) and the American College of Cardiology (ACC), the TVT Registry is designed to monitor the safety and efficacy of this new procedure for the treatment of aortic stenosis.

Study summary:

Purpose of the Registry The TVT Registry was designed to support a national surveillance system to assess the characteristics, treatments, and outcomes of patients receiving transcutaneous valve therapies. Patient-level data are submitted by participating hospitals to The Society of Thoracic Surgeons (STS) and American College of Cardiology Foundation's (ACCF) joint TVT Registry. The purposes of the TVT Registry include: (i) collecting pertinent and standardized data elements from participating hospitals, health care providers and others that measure and assess the quality of care for patients receiving TVT; (ii) providing confidential periodic reports to participating hospitals, health care providers and others, to evaluate and improve the quality of care in these areas; and (iii) permitting and fostering appropriate research based upon the data collected by means of the TVT Registry. The secondary aim of the TVT Registry is to serve as a scalable data infrastructure for post market studies. Background and Significance Transcatheter valve therapies are now emerging into clinical practice from the research phase in the United States. The first of several approaches to replacing the aortic valve without open-chest surgery has now become a reality. Other valve and delivery systems are expected to be approved in the upcoming years. An Expert Consensus Document on Transcatheter Valve Therapy has outlined the initial technology, targeted patient population, and the multidisciplinary heart team and specialized facilities needed. The document also proposes the establishment of a national registry of patients with valvular heart disease that can collect and analyze data as these new valve treatment options become available. Surveillance of device performance, monitoring of long-term outcomes, and performance of comparative effectiveness research are some of the proposed uses of the registry. Transcatheter valve therapies have emerged because of unmet patient needs. Furthermore, TVT has developed at a time when degenerative heart valve diseases of both the mitral and aortic valves are increasing in frequency as the population ages. With the introduction of the first TAVR commercial product, the targeted patient group is the "inoperable" patient who cannot receive the traditional therapy of surgical aortic valve replacement (SAVR). It is expected that TAVR will subsequently be extended to patients who have high risk with SAVR. The marked reduction of mortality by TAVR in the inoperable patients and the similar mortality of TAVR versus SAVR in the high risk patients provide patients with a new therapy with benefits but also with a different risk profile. Patients and their families will need to make informed decisions regarding the likelihood of having a mortality benefit, of improving their functional class and quality of life, of suffering a complication, and of choosing between different care options and therapeutic approaches. For these patients there are unique issues such as the prioritization of the health related quality of life versus the quantity of life, the desire to preserve independence and avoid becoming a burden to families, and the need to clearly understand what about their current condition is reversible versus irreversible and linked to other conditions and aging. These issues become further highlighted when considering the considerable costs and other treatment burdens of the TVT technologies versus the disabling symptoms and recurrent hospitalizations caused by untreated severe valvular heart disease.


Inclusion criteria: - 18 years or older

Study is Available At:

Original ID:




Secondary ID:

Study Acronym:


Brief Title:

STS/ACC Transcatheter Valve Therapy Registry (TVT Registry)

Official Title:

Society of Thoracic Surgeons and American College of Cardiology Transcatheter Valve Therapy Registry (STS/ACC TVT Registry).

Overall Status:


Study Phase:




Minimum Age:

18 Years

Maximum Age:


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

The Society of Thoracic Surgeons

Oversight Authority:

United States: Institutional Review Board

Reasons Why Stopped:

Study Type:

Observational [Patient Registry]

Study Design:

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:John D Carroll, MD
Principal Investigator
American College of Cardiology
Primary Contact:Joan Michaels
(202) 375 6309

Study Dates

Start Date:June 2012
Completion Date:June 2022
Completion Type:Anticipated
Primary Completion Date:June 2020
Primary Completion Type:Anticipated
Verification Date:July 2019
Last Changed Date:July 9, 2019
First Received Date:November 14, 2012

Study Outcomes

Outcome Type:Secondary Outcome
Time Frame:1 year
Safety Issues:False
Description:Proportion of patients who are alive with at least moderate functional improvement (defined as at least 10 point improvement in Kansas City Cardiomyopathy Questionnaire (KCCQ) from baseline) at 1 year after receiving TAVR
Outcome Type:Primary Outcome
Measure:Major adverse cardiac and cerebrovascular events
Time Frame:30 day
Safety Issues:False
Description:increase in the 30-day risk of adverse events among patients receiving TAVR

Study Interventions

Intervention Type:Procedure
Name:Transcatheter Aortic Valve Replacement
Description:Minimal invasive implantation of a biological prothesis in Aortic Position
Arm Name:TAVR Patients

Study Arms

Study Arm Type:Other
Arm Name:TAVR Patients
Description:Will include all patients 18 years or over who undergo Transcatheter Aortic Valve Replacement (TAVR) for severe aortic stenosis. The sample size will include all patients entered into the Registry.

Study Agencies

Agency Class:Other
Agency Type:Lead Sponsor
Agency Name:The Society of Thoracic Surgeons
Agency Class:Other
Agency Type:Collaborator
Agency Name:American College of Cardiology

Samples and Retentions

Study Population: Transcatheter Aortic Valve Replacement must be furnished in a hospital with the appropriate infrastructre that includes, but is not limited to On site heart valve surgery program Cardiac catheterization lab or hybrid operating room with a fixed radiographic imaging system with flat panel fluoroscopy, offering quality imaging Non-invasive imaging such as echocardiography, vascular ultrasound, computed tomography and magnetic resonance Sufficient space, in a sterile environment, to accomodate necessary equipment for cases with and without complications Post-procedure intensive care facility with personnel experienced in managing patients who have undergone open-heart valve procedures Appropriate volume requirements
Sample Method:Non-Probability Sample

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: July 25, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

If you would like to be contacted by the clinical trial representative please fill out the form below.